Vitiligo-Like Lesions in a Patient with Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor: A Case Report and Literature Review

Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic Review

(2021) Martina Silvestri et al.   DRUG SAFETY

Drug induced vitiligo‐like depigmentation from a CDK 4/6 inhibitor

(2021) On B. Chan et al.   Asia-Pacific Journal of Clinical Oncology

The role of CDK4/6 inhibitors in early breast cancer

(2021) Miguel Gil-Gil et al.   BREAST

Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future

(2020) Laura M Spring et al.   LANCET

The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC)

(2020) Daniel Eiger et al.   ACTA ONCOLOGICA

Palbociclib‐induced histiocytoid Sweet syndrome

(2020) X. Fustà‐Novell et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors

(2020) Pietro Sollena et al.   BREAST CANCER RESEARCH AND TREATMENT

Markedly Reduced Risk of Internal Malignancies in Patients With Vitiligo: A Nationwide Population-Based Cohort Study

(2019) Jung Min Bae et al.   JOURNAL OF CLINICAL ONCOLOGY

Toxic epidermal necrolysis associated with ribociclib in a patient with metastatic breast cancer

(2019) Yakup Bozkaya et al.   Breast Journal

Health‐Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor‐Positive, HER2‐Negative Advanced Breast Cancer After Endocrine Therapy

(2019) Peter A. Kaufman et al.   ONCOLOGIST

Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma

(2019) Emilien Billon et al.   Frontiers in Oncology

Chemotherapy patient with Stevens-Johnson Syndrome presents to the Emergency Department: A case report

(2018) Stephanie Widmer et al.   AMERICAN JOURNAL OF EMERGENCY MEDICINE

Prevalence of dermatological complaints in patients undergoing treatment for breast cancer

(2018) Tamara Hoffmann et al.   ANAIS BRASILEIROS DE DERMATOLOGIA

Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2

(2018) Sunil Verma et al.   BREAST CANCER RESEARCH AND TREATMENT

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

(2018) Debu Tripathy et al.   LANCET ONCOLOGY

Decreased SUMOylation of the retinoblastoma protein in keratinocytes during the pathogenesis of vitiligo

(2018) Miaoni Zhou et al.   Molecular Medicine Reports

CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials

(2018) Carlo Messina et al.   BREAST CANCER RESEARCH AND TREATMENT

290OPatient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: Results from MONALEESA-3

(2018) P A Fasching et al.   ANNALS OF ONCOLOGY

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

(2017) George W. Sledge et al.   JOURNAL OF CLINICAL ONCOLOGY

Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis

(2017) Julia Dai et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial

(2016) N. Harbeck et al.   ANNALS OF ONCOLOGY

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

(2016) Massimo Cristofanilli et al.   LANCET ONCOLOGY

Treating cancer with selective CDK4/6 inhibitors

(2016) Ben O'Leary et al.   Nature Reviews Clinical Oncology

Palbociclib and Letrozole in Advanced Breast Cancer

(2016) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab

(2016) Camille Hua et al.   JAMA Dermatology

Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis

(2015) Hansje-Eva Teulings et al.   JOURNAL OF CLINICAL ONCOLOGY

Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo

(2014) Andrea Paradisi et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Lung, liver, prostate, bladder malignancies risk in systemic lupus erythematosus: evidence from a meta-analysis

(2014) J Ni et al.   LUPUS

Alopecia With Endocrine Therapies in Patients With Cancer

(2013) V. Saggar et al.   ONCOLOGIST

Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners

(2012) H.E. Teulings et al.   BRITISH JOURNAL OF DERMATOLOGY

The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies

(2011) Yevgeniy Balagula et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Cancer risk in hospitalized rheumatoid arthritis patients

(2008) K. Hemminki et al.   RHEUMATOLOGY